BCL2 and prostate carcinoma: identified the potential pathway for α‐tomatine to inhibit prostate cancer to be through inhibiting NF‐κB activity and NF‐κB‐dependent expression of anti‐apoptotic proteins (c‐IAP1, c‐IAP2, Bcl‐2/xL, XIAP, and survivin).